#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


1-1	0-1	A	_
1-2	2-13	Preliminary	_
1-3	14-19	Study	_
1-4	20-22	of	_
1-5	23-26	DBH	_
1-6	27-28	(	_
1-7	29-37	Encoding	_
1-8	38-46	Dopamine	_
1-9	47-63	Beta-Hydroxylase	_
1-10	64-65	)	_
1-11	66-73	Genetic	_
1-12	74-83	Variation	_
1-13	84-87	and	_
1-14	88-94	Neural	_
1-15	95-105	Correlates	_
1-16	106-108	of	_
1-17	109-118	Emotional	_
1-18	119-122	and	_
1-19	123-135	Motivational	_
1-20	136-146	Processing	_
1-21	147-149	in	_
1-22	150-161	Individuals	_
1-23	162-166	With	_
1-24	167-170	and	_
1-25	171-178	Without	_
1-26	179-191	Pathological	_
1-27	192-200	Gambling	_
1-28	201-211	Background	_
1-29	212-215	and	_
1-30	216-220	aims	_
1-31	221-243	Corticostriatal-limbic	_
1-32	244-258	neurocircuitry	_
1-33	259-260	,	_
1-34	261-270	emotional	_
1-35	271-274	and	_
1-36	275-287	motivational	_
1-37	288-298	processing	_
1-38	299-300	,	_
1-39	301-313	dopaminergic	_
1-40	314-317	and	_
1-41	318-331	noradrenergic	_
1-42	332-339	systems	_
1-43	340-343	and	_
1-44	344-351	genetic	_
1-45	352-359	factors	_
1-46	360-364	have	_
1-47	365-368	all	_
1-48	369-373	been	_
1-49	374-384	implicated	_
1-50	385-387	in	_
1-51	388-400	pathological	_
1-52	401-409	gambling	_
1-53	410-411	(	_
1-54	412-414	PG	_
1-55	415-416	)	_
1-56	417-418	.	_

2-1	419-426	However	_
2-2	427-428	,	_
2-3	429-436	allelic	_
2-4	437-445	variants	_
2-5	446-448	of	_
2-6	449-454	genes	_
2-7	455-466	influencing	_
2-8	467-479	dopaminergic	_
2-9	480-483	and	_
2-10	484-497	noradrenergic	_
2-11	498-515	neurotransmitters	_
2-12	516-520	have	_
2-13	521-524	not	_
2-14	525-529	been	_
2-15	530-542	investigated	_
2-16	543-547	with	_
2-17	548-555	respect	_
2-18	556-558	to	_
2-19	559-562	the	_
2-20	563-569	neural	_
2-21	570-580	correlates	_
2-22	581-583	of	_
2-23	584-593	emotional	_
2-24	594-597	and	_
2-25	598-610	motivational	_
2-26	611-617	states	_
2-27	618-620	in	_
2-28	621-623	PG	_
2-29	624-625	.	_

3-1	626-634	Dopamine	_
3-2	635-651	beta-hydroxylase	_
3-3	652-653	(	_
3-4	654-657	DBH	_
3-5	658-659	)	_
3-6	660-668	converts	_
3-7	669-677	dopamine	_
3-8	678-680	to	_
3-9	681-695	norepinephrine	_
3-10	696-697	;	_
3-11	698-701	the	_
3-12	702-703	T	_
3-13	704-710	allele	_
3-14	711-713	of	_
3-15	714-715	a	_
3-16	716-726	functional	_
3-17	727-744	single-nucleotide	_
3-18	745-757	polymorphism	_
3-19	758-767	rs1611115	_
3-20	768-769	(	_
3-21	770-777	C-1021T	_
3-22	778-779	)	_
3-23	780-782	in	_
3-24	783-786	the	_
3-25	787-790	DBH	_
3-26	791-795	gene	_
3-27	796-798	is	_
3-28	799-809	associated	_
3-29	810-814	with	_
3-30	815-819	less	_
3-31	820-823	DBH	_
3-32	824-832	activity	_
3-33	833-836	and	_
3-34	837-840	has	_
3-35	841-845	been	_
3-36	846-852	linked	_
3-37	853-855	to	_
3-38	856-865	emotional	_
3-39	866-875	processes	_
3-40	876-879	and	_
3-41	880-889	addiction	_
3-42	890-891	.	_

4-1	892-896	Here	_
4-2	897-898	,	_
4-3	899-901	we	_
4-4	902-913	investigate	_
4-5	914-917	the	_
4-6	918-927	influence	_
4-7	928-930	of	_
4-8	931-940	rs1611115	_
4-9	941-943	on	_
4-10	944-947	the	_
4-11	948-954	neural	_
4-12	955-965	correlates	_
4-13	966-968	of	_
4-14	969-978	emotional	_
4-15	979-982	and	_
4-16	983-995	motivational	_
4-17	996-1006	processing	_
4-18	1007-1009	in	_
4-19	1010-1012	PG	_
4-20	1013-1016	and	_
4-21	1017-1024	healthy	_
4-22	1025-1035	comparison	_
4-23	1036-1037	(	_
4-24	1038-1040	HC	_
4-25	1041-1042	)	_
4-26	1043-1055	participants	_
4-27	1056-1057	.	_

5-1	1058-1065	Methods	_
5-2	1066-1071	While	_
5-3	1072-1082	undergoing	_
5-4	1083-1093	functional	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
5-5	1094-1102	magnetic	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
5-6	1103-1112	resonance	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
5-7	1113-1120	imaging	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
5-8	1121-1122	,	_
5-9	1123-1125	18	_
5-10	1126-1128	PG	http://maven.renci.org/NeuroBridge/neurobridge#Thing
5-11	1129-1132	and	_
5-12	1133-1135	25	_
5-13	1136-1138	HC	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
5-14	1139-1151	participants	_
5-15	1152-1153	,	_
5-16	1154-1157	all	_
5-17	1158-1166	European	_
5-18	1167-1176	Americans	_
5-19	1177-1178	,	_
5-20	1179-1185	viewed	_
5-21	1186-1195	gambling-	_
5-22	1196-1197	,	_
5-23	1198-1202	sad-	_
5-24	1203-1204	,	_
5-25	1205-1208	and	_
5-26	1209-1224	cocaine-related	_
5-27	1225-1235	videotapes	_
5-28	1236-1237	.	_

6-1	1238-1246	Analyses	_
6-2	1247-1254	focused	_
6-3	1255-1257	on	_
6-4	1258-1263	brain	_
6-5	1264-1274	activation	_
6-6	1275-1286	differences	_
6-7	1287-1294	related	_
6-8	1295-1297	to	_
6-9	1298-1301	DBH	_
6-10	1302-1310	genotype	_
6-11	1311-1312	(	_
6-12	1313-1325	CC/T-carrier	_
6-13	1326-1327	[	_
6-14	1328-1332	i.e.	_
6-15	1333-1334	,	_
6-16	1335-1337	CT	_
6-17	1338-1341	and	_
6-18	1342-1344	TT	_
6-19	1345-1346	]	_
6-20	1347-1348	)	_
6-21	1349-1352	and	_
6-22	1353-1362	condition	_
6-23	1363-1364	(	_
6-24	1365-1385	sad/gambling/cocaine	_
6-25	1386-1387	)	_
6-26	1388-1389	.	_

7-1	1390-1397	Results	_
7-2	1398-1400	CC	_
7-3	1401-1413	participants	_
7-4	1414-1426	demonstrated	_
7-5	1427-1434	greater	_
7-6	1435-1446	recruitment	_
7-7	1447-1449	of	_
7-8	1450-1472	corticostriatal-limbic	_
7-9	1473-1480	regions	_
7-10	1481-1482	,	_
7-11	1483-1491	relative	_
7-12	1492-1494	to	_
7-13	1495-1505	T-carriers	_
7-14	1506-1507	.	_

8-1	1508-1511	DBH	_
8-2	1512-1520	variants	_
8-3	1521-1525	were	_
8-4	1526-1530	also	_
8-5	1531-1541	associated	_
8-6	1542-1546	with	_
8-7	1547-1554	altered	_
8-8	1555-1577	corticostriatal-limbic	_
8-9	1578-1589	activations	_
8-10	1590-1596	across	_
8-11	1597-1600	the	_
8-12	1601-1610	different	_
8-13	1611-1620	videotape	_
8-14	1621-1631	conditions	_
8-15	1632-1633	,	_
8-16	1634-1637	and	_
8-17	1638-1642	this	_
8-18	1643-1654	association	_
8-19	1655-1663	appeared	_
8-20	1664-1666	to	_
8-21	1667-1669	be	_
8-22	1670-1676	driven	_
8-23	1677-1679	by	_
8-24	1680-1687	greater	_
8-25	1688-1698	activation	_
8-26	1699-1701	in	_
8-27	1702-1704	CC	http://maven.renci.org/NeuroBridge/neurobridge#Thing
8-28	1705-1717	participants	_
8-29	1718-1726	relative	_
8-30	1727-1729	to	_
8-31	1730-1740	T-carriers	_
8-32	1741-1747	during	_
8-33	1748-1751	the	_
8-34	1752-1755	sad	_
8-35	1756-1765	condition	_
8-36	1766-1767	.	_

9-1	1768-1770	CC	_
9-2	1771-1779	relative	_
9-3	1780-1782	to	_
9-4	1783-1792	T-carrier	http://maven.renci.org/NeuroBridge/neurobridge#2Level
9-5	1793-1801	subjects	_
9-6	1802-1806	also	_
9-7	1807-1815	reported	_
9-8	1816-1823	greater	_
9-9	1824-1834	subjective	_
9-10	1835-1842	sadness	_
9-11	1843-1845	to	_
9-12	1846-1849	the	_
9-13	1850-1853	sad	_
9-14	1854-1864	videotapes	_
9-15	1865-1866	.	_

10-1	1867-1878	Conclusions	_
10-2	1879-1889	Individual	_
10-3	1890-1901	differences	_
10-4	1902-1904	in	_
10-5	1905-1912	genetic	_
10-6	1913-1924	composition	_
10-7	1925-1931	linked	_
10-8	1932-1934	to	_
10-9	1935-1944	aminergic	_
10-10	1945-1953	function	_
10-11	1954-1964	contribute	_
10-12	1965-1978	significantly	_
10-13	1979-1981	to	_
10-14	1982-1991	emotional	_
10-15	1992-2002	regulation	_
10-16	2003-2009	across	_
10-17	2010-2020	diagnostic	_
10-18	2021-2027	groups	_
10-19	2028-2031	and	_
10-20	2032-2039	warrant	_
10-21	2040-2047	further	_
10-22	2048-2061	investigation	_
10-23	2062-2064	in	_
10-24	2065-2067	PG	_
10-25	2068-2069	.	_

11-1	2070-2077	Methods	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
11-2	2078-2081	and	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
11-3	2082-2091	Materials	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
11-4	2092-2104	Participants	_
11-5	2105-2107	EA	_
11-6	2108-2116	subjects	_
11-7	2117-2118	,	_
11-8	2119-2122	who	_
11-9	2123-2131	provided	_
11-10	2132-2136	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
11-11	2137-2140	and	_
11-12	2141-2148	genetic	_
11-13	2149-2153	data	_
11-14	2154-2155	,	_
11-15	2156-2160	were	_
11-16	2161-2169	included	_
11-17	2170-2174	from	_
11-18	2175-2176	a	_
11-19	2177-2183	larger	_
11-20	2184-2190	sample	_
11-21	2191-2193	of	_
11-22	2194-2206	multi-ethnic	_
11-23	2207-2218	individuals	_
11-24	2219-2220	,	_
11-25	2221-2226	whose	_
11-26	2227-2231	data	_
11-27	2232-2235	are	_
11-28	2236-2244	reported	_
11-29	2245-2254	elsewhere	_
11-30	2255-2256	.	_

12-1	2257-2259	To	_
12-2	2260-2265	avoid	_
12-3	2266-2275	potential	_
12-4	2276-2283	genetic	_
12-5	2284-2294	population	_
12-6	2295-2309	stratification	_
12-7	2310-2311	,	_
12-8	2312-2316	only	_
12-9	2317-2319	EA	_
12-10	2320-2331	individuals	_
12-11	2332-2336	were	_
12-12	2337-2345	included	_
12-13	2346-2347	:	_
12-14	2348-2350	18	_
12-15	2351-2362	individuals	_
12-16	2363-2370	meeting	_
12-17	2371-2373	PG	_
12-18	2374-2382	criteria	_
12-19	2383-2386	and	_
12-20	2387-2389	25	_
12-21	2390-2392	HC	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
12-22	2393-2401	subjects	_
12-23	2402-2403	.	_

13-1	2404-2407	All	_
13-2	2408-2416	subjects	_
13-3	2417-2421	were	_
13-4	2422-2428	native	_
13-5	2429-2436	English	_
13-6	2437-2445	speakers	_
13-7	2446-2450	with	_
13-8	2451-2453	no	_
13-9	2454-2461	history	_
13-10	2462-2464	of	_
13-11	2465-2475	neurologic	_
13-12	2476-2485	disorders	_
13-13	2486-2488	or	_
13-14	2489-2495	injury	_
13-15	2496-2497	.	_

14-1	2498-2499	A	_
14-2	2500-2510	structured	_
14-3	2511-2519	clinical	_
14-4	2520-2529	interview	_
14-5	2530-2540	determined	_
14-6	2541-2545	that	_
14-7	2546-2548	PG	http://maven.renci.org/NeuroBridge/neurobridge#Thing
14-8	2549-2557	subjects	_
14-9	2558-2561	met	_
14-10	2562-2568	DSM-IV	_
14-11	2569-2577	criteria	_
14-12	2578-2581	for	_
14-13	2582-2584	PG	http://maven.renci.org/NeuroBridge/neurobridge#Thing
14-14	2585-2587	as	_
14-15	2588-2591	the	_
14-16	2592-2599	primary	_
14-17	2600-2609	diagnosis	_
14-18	2610-2613	and	_
14-19	2614-2618	that	_
14-20	2619-2621	HC	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
14-21	2622-2630	subjects	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
14-22	2631-2634	had	_
14-23	2635-2637	no	_
14-24	2638-2644	axis-I	_
14-25	2645-2654	disorders	_
14-26	2655-2661	except	_
14-27	2662-2670	possible	_
14-28	2671-2679	nicotine	_
14-29	2680-2690	dependence	_
14-30	2691-2692	(	_
14-31	2693-2695	ND	_
14-32	2696-2697	;	_
14-33	2698-2701	one	_
14-34	2702-2704	ND	_
14-35	2705-2712	subject	_
14-36	2713-2715	in	_
14-37	2716-2719	the	_
14-38	2720-2722	HC	http://maven.renci.org/NeuroBridge/neurobridge#ParallelGroupTrial
14-39	2723-2728	group	http://maven.renci.org/NeuroBridge/neurobridge#ParallelGroupTrial
14-40	2729-2730	)	_
14-41	2731-2732	.	_

15-1	2733-2741	Detailed	_
15-2	2742-2753	participant	_
15-3	2754-2769	characteristics	_
15-4	2770-2779	including	_
15-5	2780-2782	PG	_
15-6	2783-2794	comorbidity	_
15-7	2795-2799	with	_
15-8	2800-2805	other	_
15-9	2806-2817	psychiatric	_
15-10	2818-2827	disorders	_
15-11	2828-2831	are	_
15-12	2832-2841	described	_
15-13	2842-2844	in	_
15-14	2845-2858	Supplementary	_
15-15	2859-2867	Material	_
15-16	2868-2869	I	_
15-17	2870-2871	,	_
15-18	2872-2876	with	_
15-19	2877-2888	demographic	_
15-20	2889-2900	information	_
15-21	2901-2909	provided	_
15-22	2910-2912	in	_
15-23	2913-2918	Table	_
15-24	2919-2920	1	_
15-25	2921-2922	(	_
15-26	2923-2932	including	_
15-27	2933-2944	information	_
15-28	2945-2947	on	_
15-29	2948-2951	use	_
15-30	2952-2954	of	_
15-31	2955-2958	the	_
15-32	2959-2966	Barratt	http://maven.renci.org/NeuroBridge/neurobridge#BarrattImpulsivenessQuestionnaire
15-33	2967-2980	impulsiveness	http://maven.renci.org/NeuroBridge/neurobridge#BarrattImpulsivenessQuestionnaire
15-34	2981-2986	scale	http://maven.renci.org/NeuroBridge/neurobridge#BarrattImpulsivenessQuestionnaire
15-35	2987-2988	(	_
15-36	2989-2995	BIS-11	_
15-37	2996-2997	)	_
15-38	2998-3001	and	_
15-39	3002-3007	South	_
15-40	3008-3012	Oaks	_
15-41	3013-3021	Gambling	_
15-42	3022-3028	Screen	http://maven.renci.org/NeuroBridge/neurobridge#CognitiveAbilitiesScreeningInstrument
15-43	3029-3030	(	_
15-44	3031-3035	SOGS	_
15-45	3036-3037	)	_
15-46	3038-3041	and	_
15-47	3042-3055	Supplementary	_
15-48	3056-3064	Material	_
15-49	3065-3067	II	_
15-50	3068-3069	)	_
15-51	3070-3071	.	_

16-1	3072-3082	Genotyping	_
16-2	3083-3086	DNA	_
16-3	3087-3090	was	_
16-4	3091-3100	extracted	_
16-5	3101-3105	from	_
16-6	3106-3111	whole	_
16-7	3112-3117	blood	_
16-8	3118-3119	.	_

17-1	3120-3123	The	_
17-2	3124-3127	SNP	_
17-3	3128-3137	rs1611115	_
17-4	3138-3141	was	_
17-5	3142-3151	genotyped	_
17-6	3152-3155	for	_
17-7	3156-3159	all	_
17-8	3160-3168	subjects	_
17-9	3169-3171	by	_
17-10	3172-3173	a	_
17-11	3174-3185	fluorogenic	_
17-12	3186-3187	5	_
17-13	3188-3189	’	_
17-14	3190-3198	nuclease	_
17-15	3199-3204	assay	_
17-16	3205-3207	of	_
17-17	3208-3211	the	_
17-18	3212-3218	TaqMan	_
17-19	3219-3225	method	_
17-20	3226-3231	using	_
17-21	3232-3235	the	_
17-22	3236-3239	ABI	_
17-23	3240-3245	PRISM	_
17-24	3246-3250	7900	_
17-25	3251-3259	Sequence	_
17-26	3260-3269	Detection	_
17-27	3270-3276	System	_
17-28	3277-3278	(	_
17-29	3279-3282	ABI	_
17-30	3283-3284	,	_
17-31	3285-3291	Foster	_
17-32	3292-3296	City	_
17-33	3297-3298	,	_
17-34	3299-3301	CA	_
17-35	3302-3303	)	_
17-36	3304-3305	.	_

18-1	3306-3308	No	_
18-2	3309-3320	discrepancy	_
18-3	3321-3324	was	_
18-4	3325-3333	detected	_
18-5	3334-3341	between	_
18-6	3342-3345	the	_
18-7	3346-3356	duplicates	_
18-8	3357-3360	for	_
18-9	3361-3364	one	_
18-10	3365-3367	PG	_
18-11	3368-3375	subject	_
18-12	3376-3377	,	_
18-13	3378-3381	one	_
18-14	3382-3384	HC	_
18-15	3385-3392	subject	_
18-16	3393-3394	,	_
18-17	3395-3398	and	_
18-18	3399-3402	one	_
18-19	3403-3410	control	_
18-20	3411-3417	Centre	_
18-21	3418-3419	d	_
18-22	3420-3421	’	_
18-23	3422-3427	Etude	_
18-24	3428-3430	du	_
18-25	3431-3444	Polymorphisme	_
18-26	3445-3451	Humain	_
18-27	3452-3453	(	_
18-28	3454-3468	representative	_
18-29	3469-3471	of	_
18-30	3472-3475	the	_
18-31	3476-3478	EA	_
18-32	3479-3489	population	_
18-33	3490-3491	)	_
18-34	3492-3494	in	_
18-35	3495-3498	the	_
18-36	3499-3506	quality	_
18-37	3507-3514	control	_
18-38	3515-3517	of	_
18-39	3518-3528	genotyping	_
18-40	3529-3539	procedures	_
18-41	3540-3541	.	_

19-1	3542-3551	Genotypes	_
19-2	3552-3556	were	_
19-3	3557-3559	in	_
19-4	3560-3574	Hardy–Weinberg	_
19-5	3575-3586	equilibrium	_
19-6	3587-3590	for	_
19-7	3591-3594	the	_
19-8	3595-3597	PG	_
19-9	3598-3599	,	_
19-10	3600-3602	HC	_
19-11	3603-3604	,	_
19-12	3605-3608	and	_
19-13	3609-3617	combined	_
19-14	3618-3620	PG	_
19-15	3621-3624	and	_
19-16	3625-3627	HC	_
19-17	3628-3634	groups	_
19-18	3635-3636	(	_
19-19	3637-3640	all	_
19-20	3641-3642	p	_
19-21	3643-3644	>	_
19-22	3645-3648	.05	_
19-23	3649-3650	)	_
19-24	3651-3652	.	_

20-1	3653-3665	Experimental	_
20-2	3666-3670	task	_
20-3	3671-3683	Participants	_
20-4	3684-3690	viewed	_
20-5	3691-3694	six	_
20-6	3695-3701	videos	_
20-7	3702-3704	in	_
20-8	3705-3711	random	_
20-9	3712-3715	and	_
20-10	3716-3731	counterbalanced	_
20-11	3732-3737	order	_
20-12	3738-3739	(	_
20-13	3740-3743	see	_
20-14	3744-3757	Supplementary	_
20-15	3758-3766	Material	_
20-16	3767-3770	III	_
20-17	3771-3772	)	_
20-18	3773-3774	,	_
20-19	3775-3784	including	_
20-20	3785-3788	two	_
20-21	3789-3795	videos	_
20-22	3796-3800	each	_
20-23	3801-3808	related	_
20-24	3809-3811	to	_
20-25	3812-3820	gambling	_
20-26	3821-3822	,	_
20-27	3823-3826	sad	_
20-28	3827-3830	and	_
20-29	3831-3838	cocaine	_
20-30	3839-3848	scenarios	_
20-31	3849-3851	in	_
20-32	3852-3857	which	_
20-33	3858-3864	actors	_
20-34	3865-3871	depict	_
20-35	3872-3876	each	_
20-36	3877-3885	specific	_
20-37	3886-3894	scenario	_
20-38	3895-3896	.	_

21-1	3897-3900	The	_
21-2	3901-3909	detailed	_
21-3	3910-3919	scenarios	_
21-4	3920-3923	are	_
21-5	3924-3934	previously	_
21-6	3935-3944	described	_
21-7	3945-3946	,	_
21-8	3947-3951	with	_
21-9	3952-3959	further	_
21-10	3960-3972	descriptions	_
21-11	3973-3975	in	_
21-12	3976-3989	Supplementary	_
21-13	3990-3998	Material	_
21-14	3999-4001	IV	_
21-15	4002-4003	.	_

22-1	4004-4014	Subjective	_
22-2	4015-4024	responses	_
22-3	4025-4027	to	_
22-4	4028-4034	videos	_
22-5	4035-4039	were	_
22-6	4040-4048	recorded	_
22-7	4049-4051	on	_
22-8	4052-4053	a	_
22-9	4054-4059	scale	_
22-10	4060-4062	of	_
22-11	4063-4067	0–10	_
22-12	4068-4071	and	_
22-13	4072-4080	involved	_
22-14	4081-4087	rating	_
22-15	4088-4097	emotional	_
22-16	4098-4107	intensity	_
22-17	4108-4109	,	_
22-18	4110-4118	gambling	_
22-19	4119-4124	urges	_
22-20	4125-4126	,	_
22-21	4127-4130	and	_
22-22	4131-4135	drug	_
22-23	4136-4144	cravings	_
22-24	4145-4146	.	_

23-1	4147-4152	Image	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging
23-2	4153-4164	acquisition	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging
23-3	4165-4171	Images	_
23-4	4172-4176	were	_
23-5	4177-4185	obtained	_
23-6	4186-4191	using	_
23-7	4192-4193	a	_
23-8	4194-4197	3-T	http://maven.renci.org/NeuroBridge/neurobridge#2Level
23-9	4198-4205	Siemens	_
23-10	4206-4210	Trio	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
23-11	4211-4214	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
23-12	4215-4221	system	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
23-13	4222-4230	equipped	_
23-14	4231-4235	with	_
23-15	4236-4237	a	_
23-16	4238-4246	standard	_
23-17	4247-4257	quadrature	_
23-18	4258-4262	head	_
23-19	4263-4267	coil	_
23-20	4268-4269	,	_
23-21	4270-4275	using	_
23-22	4276-4278	T2	http://maven.renci.org/NeuroBridge/neurobridge#RewardSensitivitySubscale
23-23	4279-4280	*	http://maven.renci.org/NeuroBridge/neurobridge#RewardSensitivitySubscale
23-24	4281-4291	-sensitive	http://maven.renci.org/NeuroBridge/neurobridge#RewardSensitivitySubscale
23-25	4292-4309	gradient-recalled	_
23-26	4310-4321	single-shot	_
23-27	4322-4333	echo-planar	_
23-28	4334-4339	pulse	_
23-29	4340-4348	sequence	_
23-30	4349-4350	.	_

24-1	4351-4359	Subjects	_
24-2	4360-4364	were	_
24-3	4365-4375	positioned	_
24-4	4376-4378	in	_
24-5	4379-4382	the	_
24-6	4383-4387	coil	_
24-7	4388-4391	and	_
24-8	4392-4396	head	_
24-9	4397-4406	movements	_
24-10	4407-4411	were	_
24-11	4412-4422	restrained	_
24-12	4423-4428	using	_
24-13	4429-4433	foam	_
24-14	4434-4441	pillows	_
24-15	4442-4443	.	_

25-1	4444-4454	Anatomical	_
25-2	4455-4461	images	_
25-3	4462-4464	at	_
25-4	4465-4468	the	_
25-5	4469-4479	functional	_
25-6	4480-4485	slice	_
25-7	4486-4495	locations	_
25-8	4496-4500	were	_
25-9	4501-4505	next	_
25-10	4506-4514	obtained	_
25-11	4515-4519	with	_
25-12	4520-4529	spin-echo	_
25-13	4530-4537	imaging	_
25-14	4538-4540	in	_
25-15	4541-4544	the	_
25-16	4545-4550	axial	_
25-17	4551-4556	plane	_
25-18	4557-4565	parallel	_
25-19	4566-4568	to	_
25-20	4569-4572	the	_
25-21	4573-4613	anterior-commissure/posterior-commissure	_
25-22	4614-4615	(	_
25-23	4616-4621	AC–PC	_
25-24	4622-4623	)	_
25-25	4624-4628	line	_
25-26	4629-4633	with	_
25-27	4634-4644	repetition	_
25-28	4645-4649	time	_
25-29	4650-4651	(	_
25-30	4652-4654	TR	_
25-31	4655-4656	)	_
25-32	4657-4658	=	_
25-33	4659-4662	300	_
25-34	4663-4665	ms	_
25-35	4666-4667	,	_
25-36	4668-4672	echo	_
25-37	4673-4677	time	_
25-38	4678-4679	(	_
25-39	4680-4682	TE	_
25-40	4683-4684	)	_
25-41	4685-4686	=	_
25-42	4687-4691	2.47	_
25-43	4692-4694	ms	_
25-44	4695-4696	,	_
25-45	4697-4706	bandwidth	_
25-46	4707-4708	=	_
25-47	4709-4712	300	_
25-48	4713-4721	Hz/pixel	_
25-49	4722-4723	,	_
25-50	4724-4728	flip	_
25-51	4729-4734	angle	_
25-52	4735-4736	(	_
25-53	4737-4739	FA	_
25-54	4740-4741	)	_
25-55	4742-4743	=	_
25-56	4744-4747	60°	_
25-57	4748-4749	,	_
25-58	4750-4755	field	_
25-59	4756-4758	of	_
25-60	4759-4763	view	_
25-61	4764-4765	=	_
25-62	4766-4769	220	_
25-63	4770-4771	×	_
25-64	4772-4775	220	_
25-65	4776-4778	mm	_
25-66	4779-4780	,	_
25-67	4781-4787	matrix	_
25-68	4788-4789	=	_
25-69	4790-4793	256	_
25-70	4794-4795	×	_
25-71	4796-4799	256	_
25-72	4800-4801	,	_
25-73	4802-4804	25	_
25-74	4805-4811	slices	_
25-75	4812-4816	with	_
25-76	4817-4822	slice	_
25-77	4823-4832	thickness	_
25-78	4833-4834	=	_
25-79	4835-4836	5	_
25-80	4837-4839	mm	_
25-81	4840-4843	and	_
25-82	4844-4846	no	_
25-83	4847-4850	gap	_
25-84	4851-4852	.	_

26-1	4853-4863	Functional	http://maven.renci.org/NeuroBridge/neurobridge#BloodOxygenLevel
26-2	4864-4892	blood-oxygen-level-dependent	http://maven.renci.org/NeuroBridge/neurobridge#BloodOxygenLevel
26-3	4893-4894	(	http://maven.renci.org/NeuroBridge/neurobridge#BloodOxygenLevel
26-4	4895-4899	BOLD	http://maven.renci.org/NeuroBridge/neurobridge#BloodOxygenLevel
26-5	4900-4901	)	http://maven.renci.org/NeuroBridge/neurobridge#BloodOxygenLevel
26-6	4902-4909	signals	_
26-7	4910-4914	were	_
26-8	4915-4919	then	_
26-9	4920-4928	acquired	_
26-10	4929-4933	with	_
26-11	4934-4935	a	_
26-12	4936-4947	single-shot	_
26-13	4948-4956	gradient	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
26-14	4957-4976	echo-planar-imaging	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
26-15	4977-4985	sequence	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
26-16	4986-4987	.	_

27-1	4988-4999	Twenty-five	_
27-2	5000-5005	axial	_
27-3	5006-5012	slices	_
27-4	5013-5021	parallel	_
27-5	5022-5024	to	_
27-6	5025-5028	the	_
27-7	5029-5034	AC–PC	_
27-8	5035-5039	line	_
27-9	5040-5048	covering	_
27-10	5049-5052	the	_
27-11	5053-5058	whole	_
27-12	5059-5064	brain	_
27-13	5065-5069	were	_
27-14	5070-5078	acquired	_
27-15	5079-5083	with	_
27-16	5084-5086	TR	_
27-17	5087-5092	=1500	_
27-18	5093-5095	ms	_
27-19	5096-5097	,	_
27-20	5098-5100	TE	_
27-21	5101-5102	=	_
27-22	5103-5105	27	_
27-23	5106-5108	ms	_
27-24	5109-5110	,	_
27-25	5111-5120	bandwidth	_
27-26	5121-5122	=	_
27-27	5123-5127	2520	_
27-28	5128-5136	Hz/pixel	_
27-29	5137-5138	,	_
27-30	5139-5141	FA	_
27-31	5142-5146	=60°	_
27-32	5147-5148	,	_
27-33	5149-5154	field	_
27-34	5155-5157	of	_
27-35	5158-5162	view	_
27-36	5163-5164	=	_
27-37	5165-5168	220	_
27-38	5169-5170	×	_
27-39	5171-5174	220	_
27-40	5175-5177	mm	_
27-41	5178-5179	,	_
27-42	5180-5186	matrix	_
27-43	5187-5188	=	_
27-44	5189-5191	64	_
27-45	5192-5193	×	_
27-46	5194-5196	64	_
27-47	5197-5198	,	_
27-48	5199-5201	25	_
27-49	5202-5208	slices	_
27-50	5209-5213	with	_
27-51	5214-5219	slice	_
27-52	5220-5229	thickness	_
27-53	5230-5231	=	_
27-54	5232-5233	5	_
27-55	5234-5236	mm	_
27-56	5237-5240	and	_
27-57	5241-5243	no	_
27-58	5244-5247	gap	_
27-59	5248-5249	.	_

28-1	5250-5253	Six	_
28-2	5254-5258	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
28-3	5259-5263	runs	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
28-4	5264-5265	(	_
28-5	5266-5269	two	_
28-6	5270-5273	per	_
28-7	5274-5283	condition	_
28-8	5284-5285	)	_
28-9	5286-5290	were	_
28-10	5291-5299	acquired	_
28-11	5300-5301	.	_

29-1	5302-5311	Following	_
29-2	5312-5322	functional	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
29-3	5323-5330	imaging	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
29-4	5331-5332	,	_
29-5	5333-5348	high-resolution	_
29-6	5349-5352	3-D	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
29-7	5353-5375	Magnetization-Prepared	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
29-8	5376-5390	Rapid-Gradient	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
29-9	5391-5395	Echo	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
29-10	5396-5397	(	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
29-11	5398-5404	MPRAGE	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
29-12	5405-5406	)	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
29-13	5407-5411	data	_
29-14	5412-5413	(	_
29-15	5414-5416	TR	_
29-16	5417-5418	=	_
29-17	5419-5423	2530	_
29-18	5424-5426	ms	_
29-19	5427-5428	;	_
29-20	5429-5431	TE	_
29-21	5432-5433	=	_
29-22	5434-5438	3.34	_
29-23	5439-5441	ms	_
29-24	5442-5443	;	_
29-25	5444-5453	bandwidth	_
29-26	5454-5455	=	_
29-27	5456-5459	180	_
29-28	5460-5468	Hz/pixel	_
29-29	5469-5470	;	_
29-30	5471-5473	FA	_
29-31	5474-5475	=	_
29-32	5476-5478	7°	_
29-33	5479-5480	;	_
29-34	5481-5486	slice	_
29-35	5487-5496	thickness	_
29-36	5497-5498	=	_
29-37	5499-5500	1	_
29-38	5501-5503	mm	_
29-39	5504-5505	;	_
29-40	5506-5511	field	_
29-41	5512-5514	of	_
29-42	5515-5519	view	_
29-43	5520-5521	=	_
29-44	5522-5525	256	_
29-45	5526-5527	×	_
29-46	5528-5531	256	_
29-47	5532-5534	mm	_
29-48	5535-5536	;	_
29-49	5537-5543	matrix	_
29-50	5544-5548	=256	_
29-51	5549-5550	×	_
29-52	5551-5554	256	_
29-53	5555-5556	)	_
29-54	5557-5561	were	_
29-55	5562-5570	acquired	_
29-56	5571-5574	for	_
29-57	5575-5588	multi-subject	_
29-58	5589-5601	registration	_
29-59	5602-5603	.	_

30-1	5604-5608	Data	_
30-2	5609-5617	analysis	_
30-3	5618-5622	Data	_
30-4	5623-5627	were	_
30-5	5628-5637	converted	_
30-6	5638-5642	from	_
30-7	5643-5650	Digital	_
30-8	5651-5658	Imaging	_
30-9	5659-5662	and	_
30-10	5663-5676	Communication	_
30-11	5677-5679	in	_
30-12	5680-5688	Medicine	_
30-13	5689-5690	(	_
30-14	5691-5696	DICOM	_
30-15	5697-5698	)	_
30-16	5699-5705	format	_
30-17	5706-5708	to	_
30-18	5709-5716	ANALYZE	_
30-19	5717-5723	format	_
30-20	5724-5729	using	_
30-21	5730-5737	XMedCon	_
30-22	5738-5739	.	_

31-1	5740-5743	The	_
31-2	5744-5749	first	_
31-3	5750-5753	six	_
31-4	5754-5761	volumes	_
31-5	5762-5764	of	_
31-6	5765-5769	each	_
31-7	5770-5780	functional	_
31-8	5781-5787	series	_
31-9	5788-5792	were	_
31-10	5793-5802	discarded	_
31-11	5803-5805	to	_
31-12	5806-5812	enable	_
31-13	5813-5819	signal	_
31-14	5820-5822	to	_
31-15	5823-5830	achieve	_
31-16	5831-5843	steady-state	_
31-17	5844-5855	equilibrium	_
31-18	5856-5857	.	_

32-1	5858-5868	Functional	_
32-2	5869-5875	images	_
32-3	5876-5880	were	_
32-4	5881-5886	first	_
32-5	5887-5907	slice-time-corrected	_
32-6	5908-5911	and	_
32-7	5912-5916	then	_
32-8	5917-5926	realigned	_
32-9	5927-5928	(	_
32-10	5929-5935	motion	_
32-11	5936-5945	corrected	_
32-12	5946-5947	)	_
32-13	5948-5952	with	_
32-14	5953-5956	the	_
32-15	5957-5968	Statistical	_
32-16	5969-5979	Parametric	_
32-17	5980-5987	Mapping	_
32-18	5988-5989	5	_
32-19	5990-5999	algorithm	_
32-20	6000-6001	(	_
32-21	6002-6041	www.fil.ion.ucl.ac.uk/spm/software/spm5	_
32-22	6042-6043	)	_
32-23	6044-6047	for	_
32-24	6048-6053	three	_
32-25	6054-6067	translational	_
32-26	6068-6078	directions	_
32-27	6079-6080	(	_
32-28	6081-6082	x	_
32-29	6083-6084	,	_
32-30	6085-6086	y	_
32-31	6087-6088	,	_
32-32	6089-6091	or	_
32-33	6092-6093	z	_
32-34	6094-6095	)	_
32-35	6096-6099	and	_
32-36	6100-6105	three	_
32-37	6106-6114	possible	_
32-38	6115-6124	rotations	_
32-39	6125-6126	(	_
32-40	6127-6132	pitch	_
32-41	6133-6134	,	_
32-42	6135-6138	yaw	_
32-43	6139-6140	,	_
32-44	6141-6143	or	_
32-45	6144-6148	roll	_
32-46	6149-6150	)	_
32-47	6151-6152	.	_

33-1	6153-6159	Trials	_
33-2	6160-6164	with	_
33-3	6165-6171	linear	_
33-4	6172-6178	motion	_
33-5	6179-6183	that	_
33-6	6184-6187	had	_
33-7	6188-6189	a	_
33-8	6190-6202	displacement	_
33-9	6203-6205	in	_
33-10	6206-6212	excess	_
33-11	6213-6215	of	_
33-12	6216-6217	2	_
33-13	6218-6220	mm	_
33-14	6221-6223	or	_
33-15	6224-6232	rotation	_
33-16	6233-6235	in	_
33-17	6236-6242	excess	_
33-18	6243-6245	of	_
33-19	6246-6248	3°	_
33-20	6249-6253	were	_
33-21	6254-6262	rejected	_
33-22	6263-6264	.	_

34-1	6265-6274	Corrected	_
34-2	6275-6281	images	_
34-3	6282-6286	were	_
34-4	6287-6296	spatially	_
34-5	6297-6305	smoothed	_
34-6	6306-6308	by	_
34-7	6309-6314	using	_
34-8	6315-6316	a	_
34-9	6317-6325	Gaussian	_
34-10	6326-6332	filter	_
34-11	6333-6337	with	_
34-12	6338-6339	a	_
34-13	6340-6366	full-width-at-half-maximum	_
34-14	6367-6369	of	_
34-15	6370-6375	6.876	_
34-16	6376-6378	mm	_
34-17	6379-6380	.	_

35-1	6381-6403	Analysis-of-covariance	_
35-2	6404-6405	(	_
35-3	6406-6412	ANCOVA	_
35-4	6413-6414	)	_
35-5	6415-6425	approaches	_
35-6	6426-6428	as	_
35-7	6429-6438	described	_
35-8	6439-6444	below	_
35-9	6445-6455	controlled	_
35-10	6456-6459	for	_
35-11	6460-6470	covariates	_
35-12	6471-6474	and	_
35-13	6475-6483	analyzed	_
35-14	6484-6490	signal	_
35-15	6491-6497	change	_
35-16	6498-6504	during	_
35-17	6505-6508	the	_
35-18	6509-6515	entire	_
35-19	6516-6522	period	_
35-20	6523-6525	of	_
35-21	6526-6539	video-viewing	_
35-22	6540-6548	relative	_
35-23	6549-6551	to	_
35-24	6552-6555	the	_
35-25	6556-6564	combined	_
35-26	6565-6569	pre-	_
35-27	6570-6573	and	_
35-28	6574-6587	post-baseline	_
35-29	6588-6589	(	_
35-30	6590-6593	see	_
35-31	6594-6607	Supplementary	_
35-32	6608-6616	Material	_
35-33	6617-6618	X	_
35-34	6619-6620	)	_
35-35	6621-6622	.	_

36-1	6623-6627	Post	_
36-2	6628-6631	hoc	_
36-3	6632-6638	t-test	_
36-4	6639-6650	comparisons	_
36-5	6651-6655	were	_
36-6	6656-6667	implemented	_
36-7	6668-6670	to	_
36-8	6671-6678	dissect	_
36-9	6679-6683	what	_
36-10	6684-6690	drived	_
36-11	6691-6694	the	_
36-12	6695-6702	effects	_
36-13	6703-6713	identified	_
36-14	6714-6716	in	_
36-15	6717-6720	the	_
36-16	6721-6728	ANCOVAs	_
36-17	6729-6732	and	_
36-18	6733-6741	examined	_
36-19	6742-6745	the	_
36-20	6746-6752	nature	_
36-21	6753-6755	of	_
36-22	6756-6759	the	_
36-23	6760-6767	effects	_
36-24	6768-6769	.	_

37-1	6770-6773	For	_
37-2	6774-6793	subjective-response	_
37-3	6794-6798	data	_
37-4	6799-6800	,	_
37-5	6801-6809	analyses	_
37-6	6810-6812	of	_
37-7	6813-6821	variance	_
37-8	6822-6823	(	_
37-9	6824-6830	ANOVAs	_
37-10	6831-6832	)	_
37-11	6833-6839	tested	_
37-12	6840-6862	emotional/motivational	_
37-13	6863-6870	ratings	_
37-14	6871-6878	between	_
37-15	6879-6882	the	_
37-16	6883-6885	PG	_
37-17	6886-6889	and	_
37-18	6890-6892	HC	_
37-19	6893-6899	groups	_
37-20	6900-6901	.	_

38-1	6902-6908	ANOVAs	_
38-2	6909-6915	tested	_
38-3	6916-6919	DBH	_
38-4	6920-6928	genotype	_
38-5	6929-6940	differences	_
38-6	6941-6944	for	_
38-7	6945-6948	the	_
38-8	6949-6952	sad	_
38-9	6953-6962	condition	_
38-10	6963-6964	.	_

39-1	6965-6987	Analysis-of-covariance	_
39-2	6988-6992	Data	_
39-3	6993-6997	were	_
39-4	6998-7007	converted	_
39-5	7008-7010	to	_
39-6	7011-7015	AFNI	_
39-7	7016-7022	format	_
39-8	7023-7024	(	_
39-9	7025-7029	http	_
39-10	7030-7031	:	_
39-11	7032-7051	//afni.nimh.nih.gov	_
39-12	7052-7053	)	_
39-13	7054-7057	for	_
39-14	7058-7065	ANCOVAs	_
39-15	7066-7067	.	_

40-1	7068-7070	We	_
40-2	7071-7078	applied	_
40-3	7079-7080	a	_
40-4	7081-7082	2	_
40-5	7083-7084	×	_
40-6	7085-7086	2	_
40-7	7087-7088	×	_
40-8	7089-7090	3	_
40-9	7091-7097	ANCOVA	_
40-10	7098-7102	with	_
40-11	7103-7106	age	_
40-12	7107-7117	adjustment	_
40-13	7118-7127	involving	_
40-14	7128-7131	two	_
40-15	7132-7135	DBH	_
40-16	7136-7145	genotypic	_
40-17	7146-7152	groups	_
40-18	7153-7154	(	_
40-19	7155-7167	CC/T-carrier	_
40-20	7168-7169	)	_
40-21	7170-7171	,	_
40-22	7172-7175	two	_
40-23	7176-7186	diagnostic	_
40-24	7187-7193	groups	_
40-25	7194-7195	(	_
40-26	7196-7201	PG/HC	_
40-27	7202-7203	)	_
40-28	7204-7205	,	_
40-29	7206-7209	and	_
40-30	7210-7215	three	_
40-31	7216-7226	conditions	_
40-32	7227-7228	(	_
40-33	7229-7237	gambling	_
40-34	7238-7239	,	_
40-35	7240-7243	sad	_
40-36	7244-7245	,	_
40-37	7246-7249	and	_
40-38	7250-7257	cocaine	_
40-39	7258-7259	)	_
40-40	7260-7261	,	_
40-41	7262-7264	in	_
40-42	7265-7270	which	_
40-43	7271-7278	subject	_
40-44	7279-7282	was	_
40-45	7283-7290	treated	_
40-46	7291-7293	as	_
40-47	7294-7295	a	_
40-48	7296-7302	random	_
40-49	7303-7309	factor	_
40-50	7310-7315	using	_
40-51	7316-7319	the	_
40-52	7320-7328	GroupAna	_
40-53	7329-7336	program	_
40-54	7337-7341	from	_
40-55	7342-7345	the	_
40-56	7346-7350	AFNI	_
40-57	7351-7357	MATLAB	_
40-58	7358-7365	library	_
40-59	7366-7367	(	_
40-60	7368-7372	http	_
40-61	7373-7374	:	_
40-62	7375-7407	//afni.nimh.nih.gov/afni/matlab/	_
40-63	7408-7409	)	_
40-64	7410-7411	.	_

41-1	7412-7419	Results	_
41-2	7420-7424	were	_
41-3	7425-7431	masked	_
41-4	7432-7433	,	_
41-5	7434-7443	converted	_
41-6	7444-7448	back	_
41-7	7449-7451	to	_
41-8	7452-7459	ANALYZE	_
41-9	7460-7466	format	_
41-10	7467-7470	and	_
41-11	7471-7477	viewed	_
41-12	7478-7480	in	_
41-13	7481-7485	Yale	_
41-14	7486-7494	BioImage	_
41-15	7495-7500	Suite	_
41-16	7501-7502	(	_
41-17	7503-7507	http	_
41-18	7508-7509	:	_
41-19	7510-7534	//wwww.bioimagesuite.org	_
41-20	7535-7536	)	_
41-21	7537-7538	.	_

42-1	7539-7543	Data	_
42-2	7544-7548	were	_
42-3	7549-7560	thresholded	_
42-4	7561-7563	at	_
42-5	7564-7565	a	_
42-6	7566-7571	voxel	_
42-7	7572-7577	level	_
42-8	7578-7580	of	_
42-9	7581-7582	p	_
42-10	7583-7584	<	_
42-11	7585-7588	.05	_
42-12	7589-7590	,	_
42-13	7591-7600	corrected	_
42-14	7601-7604	for	_
42-15	7605-7613	multiple	_
42-16	7614-7625	comparisons	_
42-17	7626-7628	by	_
42-18	7629-7636	spatial	_
42-19	7637-7643	extent	_
42-20	7644-7646	of	_
42-21	7647-7657	contiguous	_
42-22	7658-7674	suprathresholded	_
42-23	7675-7685	individual	_
42-24	7686-7692	voxels	_
42-25	7693-7695	at	_
42-26	7696-7697	a	_
42-27	7698-7725	family-wise-error-corrected	_
42-28	7726-7727	(	_
42-29	7728-7731	FWE	_
42-30	7732-7741	corrected	_
42-31	7742-7743	)	_
42-32	7744-7753	threshold	_
42-33	7754-7756	of	_
42-34	7757-7758	p	_
42-35	7759-7760	<	_
42-36	7761-7764	.05	_
42-37	7765-7766	.	_

43-1	7767-7769	In	_
43-2	7770-7771	a	_
43-3	7772-7783	Monte-Carlo	_
43-4	7784-7794	simulation	_
43-5	7795-7800	using	_
43-6	7801-7805	AFNI	_
43-7	7806-7807	(	_
43-8	7808-7816	applying	_
43-9	7817-7818	a	_
43-10	7819-7828	smoothing	_
43-11	7829-7835	kernel	_
43-12	7836-7838	of	_
43-13	7839-7844	6.876	_
43-14	7845-7847	mm	_
43-15	7848-7851	and	_
43-16	7852-7853	a	_
43-17	7854-7864	connection	_
43-18	7865-7871	radius	_
43-19	7872-7874	of	_
43-20	7875-7879	6.97	_
43-21	7880-7882	mm	_
43-22	7883-7885	on	_
43-23	7886-7890	3.44	_
43-24	7891-7893	mm	_
43-25	7894-7895	×	_
43-26	7896-7900	3.44	_
43-27	7901-7903	mm	_
43-28	7904-7905	×	_
43-29	7906-7907	5	_
43-30	7908-7910	mm	_
43-31	7911-7917	voxels	_
43-32	7918-7919	)	_
43-33	7920-7921	,	_
43-34	7922-7924	an	_
43-35	7925-7935	activation	_
43-36	7936-7942	volume	_
43-37	7943-7945	of	_
43-38	7946-7949	311	_
43-39	7950-7956	voxels	_
43-40	7957-7958	(	_
43-41	7959-7963	8402	_
43-42	7964-7966	µl	_
43-43	7967-7968	)	_
43-44	7969-7978	satisfied	_
43-45	7979-7982	the	_
43-46	7983-7996	FWE-corrected	_
43-47	7997-7998	p	_
43-48	7999-8000	<	_
43-49	8001-8004	.05	_
43-50	8005-8014	threshold	_
43-51	8015-8016	.	_

44-1	8017-8023	Ethics	_
44-2	8024-8027	The	_
44-3	8028-8041	investigation	_
44-4	8042-8045	was	_
44-5	8046-8053	carried	_
44-6	8054-8057	out	_
44-7	8058-8060	in	_
44-8	8061-8071	accordance	_
44-9	8072-8076	with	_
44-10	8077-8080	the	_
44-11	8081-8087	latest	_
44-12	8088-8095	version	_
44-13	8096-8098	of	_
44-14	8099-8102	the	_
44-15	8103-8114	Declaration	_
44-16	8115-8117	of	_
44-17	8118-8126	Helsinki	_
44-18	8127-8128	;	_
44-19	8129-8132	the	_
44-20	8133-8141	protocol	_
44-21	8142-8145	was	_
44-22	8146-8154	approved	_
44-23	8155-8157	by	_
44-24	8158-8161	the	_
44-25	8162-8166	Yale	_
44-26	8167-8172	Human	_
44-27	8173-8186	Investigation	_
44-28	8187-8196	Committee	_
44-29	8197-8198	.	_

45-1	8199-8202	All	_
45-2	8203-8211	subjects	_
45-3	8212-8216	were	_
45-4	8217-8226	recruited	_
45-5	8227-8234	through	_
45-6	8235-8249	advertisements	_
45-7	8250-8253	and	_
45-8	8254-8262	provided	_
45-9	8263-8270	written	_
45-10	8271-8279	informed	_
45-11	8280-8287	consent	_
45-12	8288-8293	after	_
45-13	8294-8297	the	_
45-14	8298-8304	nature	_
45-15	8305-8307	of	_
45-16	8308-8311	the	_
45-17	8312-8322	procedures	_
45-18	8323-8326	had	_
45-19	8327-8331	been	_
45-20	8332-8337	fully	_
45-21	8338-8347	explained	_
45-22	8348-8349	.	_

